Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019;29(3):168–80.
Kaguelidou F, Holstiege J, Schink T, Bezemer I, Poluzzi E, Mazzaglia G, et al. Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study. Epidemiol Psychiatr Sci. 2020;20(29): e117.
Kalverdijk LJ, Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Hoffmann F, et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012. Child Adolesc Psychiatry Ment Health. 2017;11:55.
Article PubMed PubMed Central Google Scholar
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659–74.
Article CAS PubMed Google Scholar
Vitiello B, Davico C. Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evid Based Ment Health. 2018;21(4): e10.
Bai Y, Liu T, Xu A, Yang H, Gao K. Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Saf. 2019;18(8):703–17.
Hong M, Lee SY, Han J, Park JC, Lee YJ, Hwangbo R, et al. Prescription trends of psychotropics in children and adolescents with autism based on nationwide health insurance data. J Korean Med Sci. 2017;32(10):1687–93.
Article PubMed PubMed Central Google Scholar
Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012;16(5):CD009043.
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE. 2014;9(4): e94112.
Article PubMed PubMed Central Google Scholar
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.
Article PubMed PubMed Central Google Scholar
McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–81.
Article CAS PubMed Google Scholar
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, Canadian Alliance for Monitoring E, Safety of Antipsychotics in Children guideline g. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2011;16(9):581–9.
Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15(3):217–33.
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.
Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol. 2012;22(2):157–65.
Article CAS PubMed Google Scholar
Chung YS, Shao SC, Chi MH, Lin SJ, Su CC, Kao Yang YH, et al. Comparative cardiometabolic risk of antipsychotics in children, adolescents and young adults. Eur Child Adolesc Psychiatry. 2020.
Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116–41.
Article CAS PubMed Google Scholar
Cicala G, Barbieri MA, Santoro V, Tata C, Colucci PV, Vanadia F, et al. Safety and tolerability of antipsychotic drugs in pediatric patients: data from a 1-year naturalistic study. Front Psychiatry. 2020;11:152.
Article PubMed PubMed Central Google Scholar
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
Article CAS PubMed Google Scholar
https://www.who-umc.org/vigibase/vigibase/.
Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Ther Innov Regul Sci. 2008;42:409–19.
Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, et al. features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. Clin Pharmacol Ther. 2022;111(3):605–13.
Article CAS PubMed Google Scholar
Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14–21.
Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
Article CAS PubMed Google Scholar
EMA, 2017, Guideline on good pharmacovigilance practices (GVP). Module IX Addendum I—methodological aspects of signal detection from spontaneous reports of suspected adverse reactions, 22 November 2017.
Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–32.
Article PubMed PubMed Central Google Scholar
Yoon Y, Wink LK, Pedapati EV, Horn PS, Erickson CA. Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol. 2016;26(9):822–7.
Article CAS PubMed Google Scholar
Blake KV, Saint-Raymond A, Zaccaria C, Domergue F, Pelle B, Slattery J. Enhanced paediatric pharmacovigilance at the european medicines agency: a novel query applied to adverse drug reaction reports. Paediatr Drugs. 2016;18(1):55–63.
Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Paediatr Drugs. 2014;16(4):309–19.
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225–32.
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8.
Article CAS PubMed PubMed Central Google Scholar
Sabus A, Feinstein J, Romani P, Goldson E, Blackmer A. Management of self-injurious behaviors in children with neurodevelopmental disorders: a pharmacotherapy overview. Pharmacotherapy. 2019;39(6):645–64.
Article PubMed PubMed Central Google Scholar
Sandberg L, Taavola H, Aoki Y, Chandler R, Noren GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43(10):999–1009.
Article PubMed PubMed Central Google Scholar
Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, Fuste AC, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–76.
Article CAS PubMed Google Scholar
Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiat. 2015;72(9):867–74.
Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, et al. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiat. 2020;77(2):155–64.
Chen W, Cepoiu-Martin M, Stang A, Duncan D, Symonds C, Cooke L, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clin Drug Investig. 2018;38(5):449–55.
Pozzi M, Bertella S, Cattaneo D, Molteni M, Perrone V, Carnovale C, et al. Are non-serious adverse reactions to psychiatric drugs really non-serious? J Child Adolesc Psychopharmacol. 2013;23(6):394–400.
Article CAS PubMed Google Scholar
McClellan J, Stock S, American Academy of C, Adolescent Psychiatry Committee on Quality I. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52(9):976–90.
Lee ES, Kronsberg H, Findling RL. Psychopharmacologic treatment of schizophrenia in adolescents and children. Child Adolesc Psychiatr Clin N Am. 2020;29(1):183–210.
Volpato AM, Zugno AI, Quevedo J. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics. Braz J Psychiatry. 2013;35(3):295–304.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.
留言 (0)